SLC5A2 and type 2 diabetes mellitus: As a potent inhibitor of SGLT2, ertugliflozin reduces plasma glucose and glycated haemoglobin (HbA1c) levels by increasing urinary glucose excretion without inducing excessive insulin secretion in patients with type 2 diabetes (Derosa and Maffioli, 2018).